New tracer injection could sharpen cancer detection in lymph nodes
NCT ID NCT02285192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether injecting a radioactive sugar tracer (18F-FDG) into the cervix before a PET/CT scan can better show which pelvic lymph nodes contain cancer in women with early-stage cervical or high-grade endometrial cancer. The goal is to improve surgical planning by more accurately mapping cancer spread. The trial involves 42 women and compares imaging results with lab analysis of removed lymph nodes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-Fluorodeoxyglucose (18F-FDG)
- What this could lead to
- If successful, this could provide a more accurate way to map cancer spread to lymph nodes, helping surgeons remove the right nodes and potentially improving treatment planning.
- What could go wrong
- This is a small, early-phase study with only 42 participants, so results may not apply to all patients. The technique is still experimental and may not be more accurate than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
42 people
The number who actually took part.
- Started
-
Nov 2014
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging. High grade is defined by the following: * Uterine serous carcinoma * Clear cell endometrial carcinoma * Grade 3 endometrioid carcinoma * Endometrial carcinosarcoma * Clinical stage I grade 1-2 endometrial cancer also eligible with deep myoinvasion ≥ 50% shown on preop MRI and/or elevated preop CA-125 \> 35 U/ml. * Age ≥18 years * Hemoglobin ≥10 g/dL * Plasma albumin ≥3 g/dL * GOG performance status ≤2 * Plasma glucose ≤200 mg/dL * Plasma creatinine ≤1.6 * Well-controlled hypertension * Medical clearance for surgery and considered an appropriate surgical candidate * Negative serum pregnancy test, if of child-bearing potential * If, based on surgeon's assessment, the patient is recommended to undergo surgical staging for histologically confirmed endometrial cancer or if IB1 cervical cancer is deemed eligible for surgical treatment of disease * Participation in other research protocols does not exclude a patient from participation in this study Exclusion Criteria: * Hemoglobin \<10 g/dL * Plasma albumin \<3 g/dL * GOG performance status \>2 * Plasma glucose \>200 mg/dL * Renal insufficiency with plasma creatinine \>1.6 * Uncontrolled hypertension * Patient does not meet medical clearance for surgery and is not considered an appropriate surgical candidate * Pregnancy For Stage 2: * Patient who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers of non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc. * Patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of MRI
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Consent only)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack (Consent only)
Commack, New York, United States
-
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Consent only)
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Can pulsed radiation extend life in metastatic cervical cancer?
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?